New Neural Cell Therapy Company, Oryon Cell Therapies, Emerges Focused on Neurodegenerative Conditions

Key findings

• Oryon Cell Therapies has emerged from stealth with a $21 million Series A tranche, bringing total financing (equity and grants) to $42 million.
• Ron Cohen, M.D., has been appointed CEO.
• Early Phase 1b/2a Parkinson’s data presented at AD/PD 2026 included motor improvements and neuroimaging evidence of restored dopaminergic signaling, according to the company.

Oryon Cell Therapies has emerged from stealth mode with a new $21 million tranche of its Series A financing, bringing total funding in equity and grants to $42 million, and named Ron Cohen, M.D., as CEO, who is a biopharma entrepreneur with previous experience developing, obtaining regulatory approval for, and commercializing novel medicines.

What Oryon is developing
Oryon’s lead program is an autologous neuron replacement therapy for Parkinson’s disease, aiming to restore dopaminergic function (dopamine-related signaling involved in movement control) in the brain.

The therapy is derived from the patient’s own blood cells, which are then reprogrammed into induced pluripotent stem cells (iPSCs). Using proprietary methods, the iPSCs are then differentiated into dopaminergic neurons, the cell type that degenerates in Parkinson’s disease.

Then, the neurons are implanted into the putamen, a brain region implicated in Parkinson’s motor symptoms. Because the cells are derived from the patient, Oryon says immune suppression is not required.

Oryon’s lead program is being evaluated in an ongoing Phase 1b/2a clinical trial at Brigham & Women’s Hospital/Harvard Medical School.

The financing will support completion of its ongoing Phase 1b/2a clinical trial in Parkinson’s disease, along with manufacturing scale-up and regulatory work to progress to a Phase 3.

Want to keep up on regenerative medicine? Get the weekly newsletter here.